View Older Stories View More Recent Stories

Aug 5, 2020 07:00AM Merck Animal Health Completes Acquisition of IdentiGEN
Aug 4, 2020 05:00AM Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)
Aug 3, 2020 06:40AM Merck (MRK) Animal Health Completes Acquisition of Worldwide Rights to VECOXAN Brand of Parasiticides for Ruminant Portfolio
Aug 3, 2020 06:30AM Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN® Brand of Parasiticides for Ruminant Portfolio
Jul 31, 2020 06:45AM  Merck Announces Second-Quarter 2020 Financial Results
Jul 30, 2020 07:30AM Merck (MRK) Announces Two US Regulatory Milestones for KEYTRUDA in Triple-Negative Breast Cancer
Jul 30, 2020 06:45AM Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)
Jul 29, 2020 06:46AM Merck (MRK) Announces FDA Grants Breakthrough Therapy Designation to Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With VHL- Associated RCC
Jul 29, 2020 06:45AM FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma
Jul 28, 2020 01:30PM Merck Announces Fourth-Quarter 2020 Dividend
Jul 20, 2020 01:23PM Factbox: More companies join Facebook ad boycott bandwagon
Jul 16, 2020 06:46AM Merck (MRK) Announces FDA Grants Priority Review to its NDA for Vericiguat
Jul 16, 2020 06:45AM FDA Grants Priority Review to Merck’s New Drug Application for Vericiguat
Jul 10, 2020 01:00AM MilliporeSigma Opens its Largest M Lab™ Collaboration Center in Shanghai
Jul 9, 2020 04:32PM Merck (MRK) Animal Health Receives U.S. FDA Approval of BRAVECTO Monthly Chews
Jul 9, 2020 04:30PM Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews
Jul 9, 2020 06:46AM Merck (MRK) Announces FDA Grants Priority Review to its sBLA for KEYTRUDA for Second-Line Treatment of Patients With R/R Classical Hodgkin Lymphoma
Jul 9, 2020 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Ly
Jul 8, 2020 04:30PM Merck Announces Appointment of Organon & Co. General Counsel
Jul 8, 2020 06:56AM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA Approved in EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
Jul 8, 2020 06:55AM LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
Jul 8, 2020 06:46AM Merck (MRK) and Eisai Receive CRL for KEYTRUDA plus LENVIMA Combination as First-Line Treatment for Unresectable HCC
Jul 8, 2020 06:45AM Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Jul 6, 2020 06:46AM Merck (MRK) Reports New Analyses Showing Additional Safety & Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
Jul 6, 2020 06:45AM Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
Jul 2, 2020 02:05AM Virbac completes divestment of U.S. Rights to SENTINEL® brands to MSD Animal Health
Jul 2, 2020 02:00AM Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
Jul 1, 2020 04:30PM Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction
Jul 1, 2020 06:45AM Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31
Jun 30, 2020 06:45PM FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Jun 29, 2020 04:23PM Merck (MRK) Announces FDA Approves its KEYTRUDA for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
Jun 29, 2020 04:20PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
Jun 24, 2020 05:30PM Merck (MRK) Announces FDA Approves KEYTRUDA for Treatment of Patients with Recurrent or Metastatic cSCC that is Not Curable by Surgery or Radiation
Jun 24, 2020 05:29PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
Jun 24, 2020 06:46AM Merck (MRK) Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
Jun 24, 2020 06:45AM Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
Jun 22, 2020 06:47AM Merck (MRK) Announces V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults
Jun 22, 2020 06:45AM Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults
Jun 22, 2020 06:31AM Merck (MRK) Announces KEYTRUDA Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
Jun 22, 2020 06:30AM Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥1
Jun 19, 2020 08:29AM Merck Completes Acquisition of Themis
Jun 17, 2020 04:30PM Merck Animal Health Completes Acquisition of Quantified Ag®
Jun 17, 2020 06:46AM Merck (MRK) Announces FDA Approves Second Biomarker-Based Indication for KEYTRUDA, Regardless of Tumor Type
Jun 17, 2020 06:45AM FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type
Jun 16, 2020 01:23PM Merck (MRK), Pfizer (PFE) Report SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes & Atherosclerotic Cardiovascular Disease
Jun 16, 2020 01:15PM Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Jun 15, 2020 08:00AM Merck Announces Call for Proposals for Second Cohort of Safer Childbirth Cities, Expanding Maternal Health Support Across US Cities
Jun 12, 2020 06:40PM FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers
Jun 9, 2020 04:06PM Merck (MRK) Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma Did Not Meet its Primary Endp
Jun 9, 2020 04:05PM Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinom
View More Recent Stories View Older Stories